文献速递肝胆胰外科

β-连环蛋白/沉默信息调节因子1/法尼醇X受体通路促进门静脉结扎联合肝实质离断诱导的快速肝再生

Beta-catenin/sirtuin 1/farnesoid X receptor pathway promotion of portal vein ligation and parenchymal transection-induced rapid liver regeneration.
PubMed 文献 · Surgery · 2025-03-28

该研究在小鼠模型中探讨门静脉结扎联合肝实质离断诱导肝再生的机制,通过RNA微阵列发现Sirtuin 1是关键分子;化学抑制或基因缺失Sirtuin 1会减弱肝再生,Sirtuin 1通过法尼醇X受体促进再生,β-连环蛋白也参与该过程,且其促进作用依赖Sirtuin 1;在病变肝脏模型和人类样本中得到验证。

要点

  • 门静脉结扎联合肝实质离断诱导的肝再生显著快于假手术组(P < .05)。
  • Sirtuin 1是未来残肝增殖的关键分子,抑制或缺失会减弱肝再生。
  • β-连环蛋白/ Sirtuin 1/法尼醇X受体通路激活可加速肝再生,或改善分期肝切除预后。

核心结论

  • 激活β-连环蛋白/Sirtuin 1/法尼醇X受体通路可加速门静脉结扎联合肝实质离断诱导的肝再生。

研究设计与样本

  • 建立门静脉结扎联合肝实质离断诱导肝再生小鼠模型,行RNA微阵列分析筛选候选分子。
  • 采用基因组缺失和化学调控目标分子探索其功能,并在病变肝脏模型和人类样本中验证。

主要发现

  • 门静脉结扎联合肝实质离断诱导的肝再生显著快于假手术组(P < .05)。
  • RNA微阵列显示Sirtuin 1是未来残肝增殖的关键分子。
  • 化学抑制或基因缺失Sirtuin 1均显著减弱门静脉结扎联合肝实质离断诱导的肝再生。
  • Sirtuin 1通过法尼醇X受体促进门静脉结扎联合肝实质离断诱导的肝再生。
  • 化学抑制β-连环蛋白显著损害而激活WNT/β-连环蛋白轻度增强肝再生(P < .05),Sirtuin 1缺失阻断β-连环蛋白的促进作用。

临床怎么用

  • 调控β-连环蛋白/Sirtuin 1/法尼醇X受体通路可能改善接受分期肝切除术患者的临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: By accelerating the regeneration of the future liver remnant, portal vein ligation and parenchymal transection allows for more extensive hepatectomy. Given that the mechanism remains poorly understood, the aim of this study was to investigate the mechanism of portal vein ligation and parenchymal transection-induced liver regeneration. METHODS: A portal vein ligation and parenchymal transection-induced liver regeneration mouse model was established, followed by RNA microarray analysis to identify candidate molecules. Genomic deletion and chemical manipulation of target molecules were used to explore their functions in portal vein ligation and parenchymal transection-induced liver regeneration. Validation was conducted using a diseased liver model and human samples. RESULTS: Portal vein ligation and parenchymal transection-induced liver regeneration was significantly accelerated compared with that in sham-operated mice (P < .05). An RNA microarray revealed that Sirtuin 1 is a crucial molecule in the proliferation of the future liver remnant. Regardless of whether Sirtuin 1 is inhibited chemically or through genetic deletion, portal vein ligation and parenchymal transection-induced liver regeneration is distinctly attenuated. Further investigation revealed that Sirtuin 1 promoted portal vein ligation and parenchymal transection-induced liver regeneration via the farnesoid X receptor. In addition, beta-catenin also was found to participate in the process of future liver remnant proliferation. Chemical inhibition of beta-catenin markedly impaired but activation of WNT/beta-catenin mildly enhanced portal vein ligation and parenchymal transection-induced liver regeneration (P < .05). Deletion of Sirtuin 1 blocked the facilitating effect of beta-catenin on portal vein ligation and parenchymal transection-induced liver regeneration. These findings were validated in diseased liver models and patient samples, confirming the correlation between the beta-catenin/Sirtuin 1/farnesoid X receptor pathway and portal vein ligation and parenchymal transection-induced liver regeneration. CONCLUSION: Activation of the beta-catenin/Sirtuin 1/farnesoid X receptor pathway offers critical mechanistic insights into accelerating portal vein ligation and parenchymal transection-induced liver regeneration. Modulation of beta-catenin/Sirtuin 1/farnesoid X receptor may therefore improve clinical outcomes in patients receiving staged hepatectomy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Tong Y, Gu Q, Dong B, et al. Beta-catenin/sirtuin 1/farnesoid X receptor pathway promotion of portal vein ligation and parenchymal transection-induced rapid liver regeneration. Surgery. 2025. PMID: 40157124. doi:10.1016/j.surg.2025.109343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。